Clinical trial · no report yet · Phase 2

ARC-10

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

NCT04736173 ↗
Completed
Arcus Biosciences, Inc.
Focused size, estimated: 1–150 verified statements

We haven't built an HCP commentary report on ARC-10 (front-line PD-L1-high locally advanced or metastatic NSCLC) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Indexed commentary on ARC-10 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

Indexed so far
8 posts on X
1 podcast episode

Indexed todayTypical once built

The trial

ClinicalTrials.gov

Official title: Official Title: A Phase 2 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase: Phase 2
Status: Completed
Conditions: Non Small Cell Lung Cancer; Nonsquamous Non Small Cell Lung Cancer; Squamous Non Small Cell Lung Cancer; Lung Cancer
Interventions: Domvanalimab; Zimberelimab; Carboplatin; Paclitaxel; Pemetrexed; Pembrolizumab
Arms: Arm A - Study Part 1 (Platinum-based Chemotherapy) · Active comparator
Arm B - Study Part 1 (Zimberelimab Monotherapy) · Experimental
Arm C - Study Part 1 (Domvanalimab + Zimberelimab Combination Therapy) · Experimental
Arm D - Study Part 2 (Domvanalimab + Zimberelimab Combination Therapy) · Experimental
Arm E - Study Part 2 (Pembrolizumab) · Active comparator
Enrollment: 169
Primary outcomes: Progression-free Survival (PFS)
Sponsor: Arcus Biosciences, Inc. with Gilead Sciences
Start: Feb 8, 2021
Primary completion: Sep 17, 2026
Results posted: No
Registry record: NCT04736173 · updated Oct 19, 2026

Get this report

Focused

Report, built on orderBuilt within 24 hours of confirming your order: $750

Order this report

Quoted on an estimate of the verified statements in the commentary we've indexed so far. Final coverage is set when we build it.You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded.We build it within 24 hours of confirming your order. If we can't build it to our standard, you aren't charged.

Request a free preview

Ask us to build this report. Once it's built, its free preview (summary, finding titles and coverage) is published on this page and we email you the link. The full report is sold separately. Use your work email; we'll send a link to confirm it.

For agents: .json · .md